CS
VRDN icon

Credit Suisse’s Viridian Therapeutics VRDN Stock Holding History

Credit Suisse’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$838K Buy
47,877
+6,811
+17% +$132K ﹤0.01% 2376
2023
Q4 		$894K Buy
41,066
+1,125
+3% +$17.8K ﹤0.01% 2402
2023
Q3 		$613K Sell
39,941
-9,196
-19% -$175K ﹤0.01% 2574
2023
Q2 		$1.17M Buy
49,137
+23,299
+90% +$598K ﹤0.01% 2280
2023
Q1 		$657K Buy
25,838
+1,794
+7% +$57.5K ﹤0.01% 2583
2022
Q4 		$702K Sell
24,044
-937
-4% -$21.6K ﹤0.01% 2576
2022
Q3 		$512K Buy
24,981
+7,201
+41% +$129K ﹤0.01% 2762
2022
Q2 		$206K Buy
+17,780
New +$239K ﹤0.01% 3312
2017
Q4 		– Sell
-692
Closed -$95K – 4212
2017
Q3 		$95K Buy
+692
New +$116K ﹤0.01% 4103

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Credit Suisse's VRDN Position: Q1 2024 in Review

Credit Suisse increased its Viridian Therapeutics (VRDN) stake by 17% in Q1 2024, buying an estimated $132K and bringing the position to 47,877 shares worth $838K. The position accounts for ﹤0.01% of the portfolio, ranked #2376.

Credit Suisse first reported a position in VRDN in Q3 2017 and has held it in 9 quarters since. The position peaked at $1.17M in Q2 2023. 136 funds tracked by Wall St. Rank hold VRDN as of Q1 2024.

  • Credit Suisse held 47,877 shares of Viridian Therapeutics worth $838K as of Q1 2024.
  • Credit Suisse bought 6,811 Viridian Therapeutics shares in Q1 2024, an estimated $132K.
  • Viridian Therapeutics made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2376 holding.
  • Credit Suisse first reported a position in Viridian Therapeutics in Q3 2017 and has held it in 9 quarters since.
  • Credit Suisse's Viridian Therapeutics position peaked at $1.17M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.